Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6481 to 6495 of 7707 results

  1. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued [GID-HST10038]

    Highly specialised technologies guidance
    Discontinued

  2. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued [GID-TA10892]

    Technology appraisal guidance
    Discontinued

  3. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued [GID-TAG411]

    Technology appraisal guidance
    Discontinued

  4. Pralsetinib for thyroid cancer [ID4018]

    In development [GID-TA10910] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued [GID-TA10322]

    Technology appraisal guidance
    Discontinued

  6. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued [GID-DT14]

    Diagnostics guidance
    Discontinued

  7. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued [GID-TAG413]

    Technology appraisal guidance
    Discontinued

  8. Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

    In development [GID-TA10405] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Microthane implants for breast reconstruction or breast augmentation (discontinued)

    Discontinued [GID-MT267]

    Medical technologies guidance
    Discontinued

  10. Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]

    Discontinued [GID-TA10228]

    Technology appraisal guidance
    Discontinued

  11. Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629

    In development [GID-TA10841] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Lanreotide (subcutaneous injection) for treating unresectable locally advanced or metastatic, non-progressive gastroenteropancreatic tumours [ID961]

    Discontinued [GID-TA10026]

    Technology appraisal guidance
    Discontinued

  13. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued [GID-TA10566]

    Technology appraisal guidance
    Discontinued

  14. Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]

    Discontinued [GID-TA10763]

    Technology appraisal guidance
    Discontinued

  15. Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

    In development [GID-HST10032] Expected publication date: TBC

    Highly specialised technologies guidance
    In development